Clinical TrialsSearch results for "cytarabine"
Number of results: 82
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- JALSG-AML224-PIF
- AML patients who do not achieve complete remission after a single course of induction chemotherapy
- Kiyoi Hitoshi
- 2025-08-12
Recruiting
- A multicenter phase II study of risk-stratified chemotherapy with azacitidine for children with ML-DS
- Myeloid leukemia with Down syndrome
- Hasegawa Daisuke
- 2025-05-30
Recruiting
- JALSG-AML224-FLT3-ITD
- Newly diagnosed FLT3-ITD-positive acute myeloid leukemia
- Ishikawa Yuichi
- 2025-05-30
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Recruiting
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- Acute Myeloid Leukemia
- Inoguchi Akihiro
- 2024-10-18
Recruiting
- Phase II study of the combination of Ino with mini-hyper CVD as induction therapy in childhood and AYA patients with high-risk relapsed ALL
- Acute lymphoblastinc leukemia
- Yamamoto Shohei
- 2024-09-26
Recruiting
- A randomized phase 3 trial of fludarabine/<em>cytarabine</em>/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
- Acute myeloid leukemia
- Tomizawa Daisuke
- 2024-08-20
Other
- A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- Leukemia
- Sumi Eriko
- 2024-04-10
Other
- Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory (r/r) Mantle Cell Lymphoma or r/r B-precursor Acute Lymphoblastic Leukemia
- Ikuta Mari
- 2024-01-30
Recruiting
- JCOG2201: A randomized phase III study of pola-R-CHP/High-dose methotrexate/IT vs. Pola-R-CHP/IT for diffuse large B-cell lymphoma with high risk of CNS relapse
- Untreated diffuse large B-cell lymphoma with high risk of CNS relapse
- YAMAGUCHI Motoko
- 2023-12-12